

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.
AP32738 066876.0103

Serial No.
09/955,877

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant
Said I.A. SHALABY et al.

Filing Date
September 19, 2001

Group
1654

U.S. PATENT DOCUMENTS

*Exam. Init.	Document No.	Date	Name	Class	Subclass	Filing Date if Appropriate
PP	5 8 7 6 7 2 8	03/02/1999	Kass HD et al.			
PP	5 8 7 4 8 0 4	02/23/1999	Rogers SP			
PP	5 6 4 8 0 8 9	07/15/1997	Shawkat T			

FOREIGN PATENT DOCUMENT

Document No.	Date	Country	Class	SubClass	Translator Yes No
7 9 3 9 6 4	09/10/1999	Europe (EP)			

OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)

	Harvard School of Public Health Jan 2004, < http://www.researchmatters.harvard.edu/story.php?article_id=673 >
	Buckwold, Beer, Donis, 2003 "Bovine viral diarrhea as a surrogate model of hepatitis C virus for the evaluation of anti-viral agents" Antiviral Research Vol 60(1):1-15;
	Cost of Developing a New Drug Increases to About \$1.7 Billion By PETER LANDERS, Wall Street Journal December 8, 2003 < http://online.wsj.com/article/0,,SB107083909136415400-email,00.html >
	Enfuvirtide (Fuzeon) for HIV Infection Med Lett Drugs Ther. 2003 Jun 23; 45(1159): 49-50;
	El-Awady, et al., Chem. Clinical Acta, 283(1-2):1-14 (1999)
	McHutchison et al Interferon Alpha-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C, New England Journal of Medicine Vol 339 Number 21 November 19, 1998, 1485-1492;

NY02:472768.1

Examiner

Date Considered

4/14/04

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.
AP32738 066876.0103

Serial No.
09/955,877


INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant
Said I.A. SHALABY et al.

Filing Date
September 19, 2001

Group
1654



Yokozbawa, et al., J. Traditional Medicine, 15(4):202-207 (1998)

Alter, M.J., Hepatology, 26(1):625-655 (1997)

Alam, et al., Phytotherapy Research, 10(1):58-61 (1996);

D.S. Chen, J. Formos. Med. Assoc., 95(1):6-12 (1996);

Detre, et al., Viral Hepatitis Rev., 2:219-228 (1996);

D.C. Dale and D.D. Federman, eds. Medicine Sc. Amer., Inc., New York, 4(8):1-8 (1995);

Hipps, et al., Infect. Dis. 168:789-790 (1993);

Lok, et al., Gastroenterology, 105(6):1833-1838 (1993);

Fields, Virology 2nd ed, New York, Raven Press, 1990 p691;

Medicinal Plants of North Africa, Loutfy Boulos, Reference Publications, Inc., pp.150-51 (1983);

Medicinal Plants of North Africa, pp. 74-75 (1983);

Bergmeyer and Horder, Clin. Chem. Acta 105:147 f. (1980);

Encyclopedia of Common Natural Ingredients, Used in Food, Drugs, and Cosmetics, p.169 (1980);

International Federation of Clinical Chemistry, Scientific Committee, J. Clin. Chem. Biochem., 18:521-534 (1980);

NY02:472768.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.
AP32738 066876.0103

Serial No.
09/955,877


INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant
Said I.A. SHALABY et al.

Filing Date
September 19, 2001

Group
1654



Bergmeyer H. U. Principles of Enzymatic Analysis. Verlag Chemic, (1978);

Babbar, et al., Ind. J. Exp. Biol., 8:304-312 (1970);

Linus Pauling, General Chemistry, New York, Raven Press 1970, p 744

No Copies

NY02:472768.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.